Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

189.28 -1.47 (-0.77%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
81 82 Next >
The Smartest Dividend Stocks to Buy With $250 Right Now
$250 will go a long way with these great dividend stocks. 
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
Via Benzinga
Looking At AbbVie's Recent Unusual Options Activity
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
AbbVie Stock Price Forecast: $200 On The Cards?
Strategic partnerships and acquisitions enhance AbbVie's pipeline. 
Via Talk Markets
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors 
Via MarketBeat
Topics ETFs
New Golden Investment: Universal Health Realty Income Trust
A Golden Investment is one in which I have fully recovered my entire investment either through dividends or from partial liquidation or a combination of both. 
Via Talk Markets
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
These Dividend Aristocrats all have payouts yielding three times or more the average yield of the S&P 500. 
Via InvestorPlace
Topics Stocks
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Are you looking to boost your portfolio with the best under-the-radar biotech stocks? Here are the top three. 
Via InvestorPlace
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
3 Retirement All-Stars for Steady Growth and Income
Retirement stocks lead the pack with steady dividends and strong growth potential. Invest smartly for a worry-free retirement. 
Via InvestorPlace
Topics Retirement
Cash Flow Alert: 3 Stocks That Just Raised Their Dividends
These dividend growth stocks all have a long history of double-digit dividend increases and just announced another. 
Via InvestorPlace
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
These reliable dividend payers are no-brainer buys right now. 
Via The Motley Fool
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet
Undiscovered small-cap stocks hold the greatest potential for creating investor wealth as they can take off at a moment's notice. 
Via InvestorPlace
7 Dividend Kings to Buy With Your Roth IRA Money in 2024
These seven Dividend Kings offer reliable income streams and long-term growth potential, making them ideal holdings for your Roth IRA. 
Via InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Can AbbVie Stock Keep Outpacing the S&P 500?
AbbVie has been a surprisingly strong performer of late. Can the stock keep it up? 
Via The Motley Fool
Topics Stocks
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock
AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues. ABBV-951, a treatment for advanced Parkinson's, is approved in 34... 
Via Benzinga
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true. 
Via The Motley Fool
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets. 
Via InvestorPlace
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
3 Biotech Stocks to Buy Now: June 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024
Discover top retirement stocks with strong buy ratings, offering reliable growth and income to ensure a comfortable retirement. 
Via InvestorPlace
Topics Retirement
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding can build huge amounts of passive income. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.